Hope in Patients With Progressive Fibrosis Interstitial Lung Disease (PF-ILD)

Synopsis: In patients with progressive fibrosis interstitial lung disease, the use of nintedanib is associated with a significantly lower rate of decline in annual forced vital capacity (−80.8 mL/y with nintedanib and −187.8 mL/y with placebo). Patients on nintedanib had a higher rate of diarrhea (66.9% vs. 23.9%) and transaminitis. Source: Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases (INBUILD). N Engl J Med. Doi:10.1056/NEJMoa1908681.
Source: Clinical Pulmonary Medicine - Category: Respiratory Medicine Tags: Pulmonary Trends Source Type: research